| Primary information |
|---|
| ID | antitb_1802 |
| Peptide Name | Peptide-46 |
| Sequence | βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-Dpr-Dpr |
| N-terminal Modification | Acetylation |
| C-terminal Modification | Amidation |
| Chemical Modification | βAla = beta-alanine, Fpa, 4-fluorophenylalanine, Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
| Linear/ Cyclic | Linear |
| Length | 19 |
| Chirality | L |
| Nature | Amphipathic, Hydrophobic |
| Source | Synthetic |
| Origin | NA |
| Species | Mycobacterium ranae |
| Strain | Mycobacterium ranae (ATCC 110) |
| Inhibition Concentartion | MIC = 100 µM or 228 µg/mL |
| In vitro/In vivo | Both |
| Cell Line | NA |
| Inhibition Concentartion | NA |
| Cytotoxicity | Not tested |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Response | Stimulate innate immune system |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other Activities | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
| Pubmed ID | 17547385 |
| Year of Publication | 2007 |
| 3-D Structure | NA |